Clinical Trial Update: FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy [Phase 4]

View source ↗

Summary

This Phase 4 trial evaluated pegfilgrastim given in the first and subsequent cycles of myelosuppressive chemotherapy to prevent neutropenia. The study is comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neutropenia

Drugs mentioned

• NEULASTA (pegfilgrastim)

Snippet

Sponsor: Amgen | Conditions: Neutropenia | Phase 4 | Status: COMPLETED